Reviewed by Christian Espinosa, MBA, CISSP · Founder & CEO
Published April 2026 · Last reviewed May 2026
Episode 67 · The Med Device Cyber Podcast · with Brent Lavin, Ironwood MedTech Partners · April 23, 2026 In this interview, Brent Lavin of Ironwood MedTech Partners, discusses de-risking product decisions for MedTech startups, especially when it comes to medical device cybersecurity and regulatory compliance. He emphasizes the importance of deeply understanding customer needs and the clinical workflow early in the product design process to avoid costly reworks, a common pitfall for many innovators. Lavin highlights the need for strategic trade-offs in product features, differentiating between essential and “nice-to-have” functionalities to streamline development and regulatory pathways.The discussion also explores the complexities of market adoption and reimbursement strategies, stressing the influence of economic buyers in hospitals. Lavin advocates for a “bottom-up” approach to revenue projection, focusing on tangible sales tactics rather than high-level market sizing. He shares insights on the advantages of being a “second-mover” in the market, learning from predecessors' clinical trial experiences and regulatory navigation. The episode touches upon the strategic utilization of 510(k) and PMA pathways, weighing quicker market entry against the ability to make differentiated clinical claims. Lavin underscores that success in MedTech requires an integrated approach, balancing engineering, marketing, and regulatory perspectives to launch impactful, sticky, and sustainable medical devices.
Key Takeaways
- Prioritize customer interactions and clinical workflow understanding at the forefront of product design to avoid costly reworks and ensure market acceptance.
- Make smart, cogent product decisions by differentiating between essential and 'nice-to-have' features, satisfying the majority's needs without over-complicating the device.
- Develop a 'bottom-up' revenue ramp strategy focusing on specific sales tactics and real-world adoption, rather than solely relying on top-down total addressable market (TAM) figures.
- Consider the advantages of being a 'second mover' in the MedTech market, as it allows learning from the initial innovator's clinical trial and regulatory experiences.
- Carefully weigh the trade-offs between a faster 510(k) regulatory pathway, which may limit clinical claims, and a longer PMA pathway, which allows for differentiated claims and potentially higher margins.
- Embrace an iterative product development process, treating marketing and product management as sciences that involve hypothesizing, testing, gathering feedback, and making continuous adjustments.
- Focus on product stickiness and customer retention as key metrics for long-term business model scalability and attractiveness to strategic partners.
- Strategically choose between capital, disposable, or mixed business models for devices, performing scenario analysis to align with overall company goals and market dynamics.
Listen on mdcpodcast.com · Watch on YouTube
Listen to this episode
Want help applying this to your own device program?
Blue Goat Cyber is a specialist medical device cybersecurity firm: 250+ FDA submissions, zero rejections. If anything in this conversation hit close to home, book a 30-minute strategy session - no cost, no obligation.